Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | DRD4 | P21917 | 10/20 | 0.47 |
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173142 | 0.96 | LMNA (0.53) | LMNADRD4DRD2ALDH1A1GAA | |
| SCHEMBL97212 | 0.93 | LMNA (0.51) | LMNADRD4DRD2ALDH1A1GAA | |
| SCHEMBL10223337 | 0.83 | LMNA (0.72) | LMNADRD4DRD2ALDH1A1GAA | |
| SCHEMBL173141 | 0.83 | LMNA (0.57) | LMNADRD4DRD2ALDH1A1GAA | |
| SCHEMBL18406324 | 0.82 | LMNA (0.48) | LMNADRD4DRD2ALDH1A1GAA | |
| SCHEMBL17092565 | 0.79 | GLA (0.50) | LMNAALDH1A1GAAKDM4ETDP1 | |
| SCHEMBL2698834 | 0.77 | LMNA (0.62) | LMNADRD4DRD2TDP1SMN1; SMN2 | |
| SCHEMBL12422454 | 0.76 | KDM4E (0.46) | LMNAALDH1A1GAAKDM4ETDP1 | |
| SCHEMBL13891352 | 0.76 | LMNA (0.51) | LMNADRD4DRD2ALDH1A1GAA | |
| SCHEMBL12422449 | 0.75 | KDM4E (0.48) | LMNAALDH1A1GAAKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059008-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CENERX BIOPHARMA, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080548-B2 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | CENERX BIOPHARMA, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080548-B2 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | CENERX BIOPHARMA, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100099678-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CENERX BIOPHARMA (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099678-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CENERX BIOPHARMA (US) | 2010-04-22 | — | — | US | disclosed |
| US-7632836-B2 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | CENERX BIOPHARMA, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632836-B2 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | CENERX BIOPHARMA, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090111813-A1 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | CENERX BIOPHARMA, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111813-A1 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | CENERX BIOPHARMA, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008066874-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CENERX BIOPHARMA, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059008-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PMP22, CNR2, COQ8A | LMNA 2409/4885DRD4 590/4885DRD2 314/4885 |
| US-20100099678-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PMP22, CNR2, COQ8A | LMNA 2409/4885DRD4 590/4885DRD2 314/4885 |
| US-20090111813-A1 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | PMP22, CNR2, COQ8A | LMNA 2409/4885DRD4 590/4885DRD2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.